Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer

Table 1 Cetuximab combined with cytotoxic chemotherapeutic regimens for the first-line treatment of advanced colorectal cancer

Name of study	Clinical trial phase	n	Chemotherapy	OS (mo)	PFS (mo)
FIRE-3[55-57]	3	171	Cmab + FOLFIRI	33.1	10.2
CALGB80405[12]	3	547	Cmab + CT	29.93	10.5
COIN[58]	3	279	Cmab + FOLFOX	14.9	8.5
COIN	3	523	Cmab + CAPOX	15.0	7.4
Souglakos et al[59]	2	167	Cmab + FOLFIRI	25.7	10.0
Souglakos et al[59]	2	166	Cmab + CAPIRI	27.5	8.9
CELIM[60,61]	3	56	Cmab + FOLFOX6	35.7	11.2
CELIM	3	55	Cmab + FOLFIRI	29.0	10.5
CECOG/CORE1.2.001[62]	2	74	Cmab + FOLFOX6	17.4	8.6
CECOG/CORE1.2.001	2	77	Cmab + FOLFIRI	18.9	8.3
CRYSTAL[63,64]	3	316 (WT)	Cmab + FOLFIRI	23.5	9.9
Nordic VII[65]	3	97 (WT)	Cmab + Nordic FLOX(bolus)	20.1	7.9
COIN[66]	3	362 (WT)	Cmab + CAPOX/FOLFOX	17.0	8.6
Borner[67]	2	37	Cmab + CAPOX	20.5	7.2
OPUS[68,69]	2	82 (WT)	Cmab + FOLFOX4	18.3	7.2

OS: Overall survival; PFS: Progression-free survival; Cmab: Cetuximab; N: Number of patients analyzed in the study; CRC: Colorectal cancer; WT: Wild type; CT: Chemotherapy treatment; FOLFIRI: Leucovorin + 5-fluorouracil + irinotecan; FOLFOX: Leucovorin + 5-fluorouracil + oxaliplatin; CAPOX: Capecitabine + oxaliplatin; CAPIRI: Capecitabine + irinotecan; Nordic FLOX: 5-fluorouracil/leucovorin bolus + oxaliplatin.